CHEYENNE, Wyoming, Feb. 24, 2017 /PRNewswire/ -- Xynomic Pharmaceuticals, Inc., an oncology drug research and development company, today announced thatit has acquired exclusive worldwide rights to develop, manufacture and commercialize Abexinostat, a potentially best-in-class innovative HDAC inhibitor targeting hematological and solid tumors.
To date a total of 14 Phase 1 and 2 clinical trials
"We are honored and excited to forge this landmark agreement. We will deploy necessary resources and closely work with KOLs to expeditiously bring this innovative drug to the market to address unmet medical needs," said Mr. Y. Mark Xu, Co-Founder, Chairman and CEO of Xynomic.
About Xynomic Pharmaceuticals, Inc.
A US company founded by seasoned biopharmaceutical executives and successful entrepreneurs, Xynomic focuses on in-licensing, developing and commercializing oncology drug candidates in US, Asia, EU and rest of the world. The founding executives worked at leading multinational biopharmaceutical companies (Schering, Eli Lilly, Merck and Roche) in R&D roles. The founders also had successful entrepreneurial experiences including founding, building and exiting successful US-China biopharmaceutical companies.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/xynomic-pharma-has-acquired-worldwide-rights-of-abexinostat--300413179.html
SOURCE Xynomic Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!